NEW YORK (GenomeWeb News) – Response Biomedical has completed a 20-for-one share consolidation, the Vancouver, British Columbia-based firm said yesterday after the close of the market.

The diagnostics firm said that it expects its post-consolidation common shares will begin trading on the Toronto Stock Exchange and the OTC Bulletin Board in the US on Sept. 26. It announced the share consolidation last month.

The shares were trading at $.08 on the OTC Bulletin Board, with no shares trading hands, early Tuesday afternoon.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.

Cancer clinical trial patients settle with Anil Potti and Duke University.

A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.

Two Johns Hopkins researchers discuss the need for evidence-based data analysis.